Imaging of ulcerative colitis
https://libcat.nshealth.ca/en/permalink/provcat33766
Massimo Tonolini, editor.
--Milan:
Springer
, c2014.
- Available Online
- View e-Book
- Location
- Online
During the past decade, the medical and surgical treatment of ulcerative colitis has undergone dramatic advances, including the widespread use of immunomodulators, biological drugs, and restorative proctocolectomy. In order to correctly balance the risks and benefits of medical therapies and surgical procedures, there is a need for improved diagnosis of colonic disease, acute complications, extraintestinal manifestations, and early and delayed postoperative complications. Cross-sectional imagin…
- Available Online
- View e-Book
- Other Authors
- Tonolini, Massimo
- Responsibility
- Massimo Tonolini, editor
- Place of Publication
- Milan
- Publisher
- Springer
- Date of Publication
- c2014
- Physical Description
- 1 online resource (x, 143 pages)
- ISBN
- 9788847054097 (electronic bk.)
- 9788847054080
- Subjects (MeSH)
- Colitis, Ulcerative - diagnostic imaging
- Colitis, Ulcerative - diagnosis
- Radiography
- Subjects (LCSH)
- Ulcerative colitis - Imaging
- Ulcerative colitis - Diagnosis
- Colitis, Ulcerative - radiography
- Colitis, Ulcerative - diagnosis
- Diagnostic Imaging - methods
- Diagnostic Radiology
- Gastroenterology
- Proctology
- Abdominal surgery
- Abstract
- During the past decade, the medical and surgical treatment of ulcerative colitis has undergone dramatic advances, including the widespread use of immunomodulators, biological drugs, and restorative proctocolectomy. In order to correctly balance the risks and benefits of medical therapies and surgical procedures, there is a need for improved diagnosis of colonic disease, acute complications, extraintestinal manifestations, and early and delayed postoperative complications. Cross-sectional imaging techniques are therefore playing an increasing role in the assessment of ulcerative colitis and provide an essential complement to clinical data and endoscopy. This practical, illustrated volume on the role of cross-sectional imaging is aimed at radiologists, gastroenterologists, and surgeons who are engaged or interested in the diagnosis and care of patients with inflammatory bowel disease, particularly ulcerative colitis. After an overview of diagnostic imaging techniques, state-of-the-art assessment of colorectal inflammatory disease with CT colonography using water enema and bowel MRI is discussed, followed by description of the plain radiographic and CT findings in patients with acute exacerbations and surgical complications. Subsequent chapters review the diagnostic findings and role of cross-sectional imaging in the assessment of sclerosing cholangitis (with emphasis on MR cholangiopancreatography), vascular complications (particularly portal and mesenteric thrombosis), colitis-associated colorectal cancer and perianal inflammatory disease. Normal postoperative appearances and early and delayed complications in patients treated with proctocolectomy and ileal pouch-anal anastomosis are also comprehensively reviewed.
- Contents
- Introduction -- Medical Needs -- Intestinal Ultrasound in Ulcerative Colitis -- Water Enema Multidetector CT Colonography: Technique, Role and Imaging Findings in Ulcerative Colitis -- Magnetic Resonance Imaging of Ulcerative Colitis -- Radiographic and CT Imaging Assessment of Acute Exacerbations and Surgical Complications -- Cross-Sectional Imaging Mimics of Ulcerative Colitis -- Hepato-Bilio-Pancreatic Complications of Ulcerative Colitis -- Vascular Complications of Ulcerative Colitis -- Neoplasms in Ulcerative Colitis -- Musculoskeletal Manifestations of Ulcerative Colitis -- Surgical Perspective on Perianal Complications in Ulcerative Colitis -- Imaging of Perianal Inflammatory Disorders in Ulcerative Colitis -- Ileal Pouch-Anal Anastomosis Surgery: Surgical Techniques -- Imaging of Ileal Pouch Surgery and Related Complications.
- Format
- e-Book
- Location
- Online
Ulcerative proctitis
https://libcat.nshealth.ca/en/permalink/chpams35311
Nova Scotia Health Authority. GI Clinic.
Halifax, NS:
Nova Scotia Health Authority
, 2021.
- Pamphlet Number
- 1422
- Available Online
- View Pamphlet
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. GI Clinic
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2021
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (4 p.) : digital, PDF file
- Subjects (MeSH)
- Colitis, Ulcerative
- Inflammatory Bowel Diseases
- Subjects (LCSH)
- Ulcerative colitis
- Inflammatory bowel diseases
- Abstract
- Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
- Responsibility
- Prepared by: GI Clinic
- Pamphlet Number
- 1422
Ustekinumab (Stelara) therapy
https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1695
- Available Online
- View Pamphlet
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taki…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (10 p.) : digital, PDF file
- Subjects (MeSH)
- Ustekinumab
- Inflammatory Bowel Diseases - drug therapy
- Subjects (LCSH)
- Inflammatory bowel diseases
- Crohn's disease
- Ulcerative colitis
- Specialty
- Medications
- Abstract
- Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taking ustekinumab and while you are taking it are listed. Possible side effects, information about pregnancy and breast/chest feeding, and other important things to know are included.
- Notes
- Previous title: Ustekinumab (Stelara) therapy for Crohn's disease
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1695
Vedolizumab (Entyvio) therapy
https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program.
Halifax, NS:
Nova Scotia Health Authority
, 2022.
- Pamphlet Number
- 1623
- Available Online
- View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
- Available Online
- View Pamphlet
- Corporate Author
- Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
- Place of Publication
- Halifax, NS
- Publisher
- Nova Scotia Health Authority
- Date of Publication
- 2022
- Format
- Pamphlet
- Language
- English
- Physical Description
- 1 electronic document (11 p.) : digital, PDF file
- Subjects (MeSH)
- Gastrointestinal Agents
- Colitis, Ulcerative - drug therapy
- Crohn Disease - drug therapy
- Subjects (LCSH)
- Gastrointestinal agents
- Ulcerative colitis
- Crohn's disease
- Specialty
- Medications
- Abstract
- Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
- Responsibility
- Prepared by: Nova Scotia Collaborative IBD Program
- Pamphlet Number
- 1623
